Current incidence and residual risk of hepatitis B infection among blood donors in the United States

Zou, Shimian; Stramer, Susan L.; Notari, Edward P.; Kuhns, Mary C.; Krysztof, David E.; Musavi, Fatemeh; Fang, Chi; Dodd, Roger Y.

doi:10.1111/j.1537-2995.2009.02195.x

Cited by 107 publications

(131 citation statements)

References 21 publications

Supporting

Mentioning

124

Contrasting

Unclassified

Order By: Relevance

“…Viral disease transmission is now a rare complication of transfusion with the risk significantly decreased with the advent of nucleic acid testing for hepatitis B virus (HBV), HCV, HIV25 26 and West Nile virus 27. Parasitic infections are a rare complication with the risk greatest in endemic areas.…”

Section: Advances In Defining Risksmentioning

confidence: 99%

Recent advances toward defining the benefits and risks of erythrocyte transfusions in neonates

Christensen

Ilstrup

2012

Arch Dis Child Fetal Neonatal Ed

View full text Add to dashboard Cite

Section: Advances In Defining Risksmentioning

confidence: 99%

Recent advances toward defining the benefits and risks of erythrocyte transfusions in neonates

Christensen

Ilstrup

2012

Arch Dis Child Fetal Neonatal Ed

View full text Add to dashboard Cite

“…In this geographic context, in a few cases (3.41 per 10 5 personsyears), the presence of this serological profile has been associated with recent seroconversion, estimated by the incidence-window period model proposed by Zou et al [85]. On the other hand, in regions with high prevalence of HBV infection (and consequently, higher rates of chronic infection, vertical transmission and mutation), prevalence of HBsAg isolated profile serological tends to be increased and may correspond to almost 50% among specimens with unusual serological profile, being often related to the altered immune response of the host or to HBV variants [86].…”

Section: Prevalence Of Isolated Positivity For Hbsag Serological Profilementioning

confidence: 99%

The underlying mechanisms for the “isolated positivity for the hepatitis B surface antigen (HBsAg)” serological profile

Pondé

2010

Med Microbiol Immunol

View full text Add to dashboard Cite

During HBV infection, four structural antigen/antibody systems are observed: hepatitis B surface antigen (HBsAg) and its antibody (anti-HBs); the pre-S antigens associated with HBsAg particles and their antibodies; the particulate nucleocapsid antigen (HBcAg) and anti-HBc; and an antigen structurally related to HBcAg, namely HBeAg and its antibody (anti-HBe). Through the examination of this antigen-antibodies system, hepatitis B infection is diagnosed and the course of the disorder may be observed. Isolated HBsAg seropositivity is a peculiar serological pattern in HBV infection observed some times in routine laboratory. In most cases is not clear how this profile should be interpreted neither its significance. This pattern, however, may be associated with some clinical and laboratorial situations of great relevance, some of which will be addressed in this article.

show abstract

“…For example, about 100 West-Nile-infected donations were estimated removed from the USA blood supply in 2003 [15]. Using revised HBV window period of 30-38 days, a marked reduction in the HBV residual risk was calculated from 1 : 86.000-1 : 110.000 in 1997-99 to 1 : 280.000-1 : 355.000 in 2006-8 [16]. The most recent estimates of the HBV residual risk in the USA were approximately 1 : 300.000 [17].…”

Section: Developed Countriesmentioning

confidence: 99%

“…Another method for estimating HBV incidence and residual risk was named "HBsAg yield method" [16,85,86]. It requires both HbsAg and anti-HBc serologic markers.…”

Section: Hbsag Yieldmentioning

confidence: 99%

Residual Risk of Hepatitis-B-Infected Blood Donations: Estimation Methods and Perspectives

Kupek

2013

ISRN Infectious Diseases

View full text Add to dashboard Cite

Despite a considerable reduction of the risk of HBV-infected blood donation entering blood supply (residual risk) due to improved screening by HBV NAT in the developed countries, the bulk of the people with HBV living in the developing countries still needs to be screened by serologic tests such as HBsAg and anti-HBc. Many of these countries lack resources for implementing NAT and are likely to remain so in the next decade or longer, thus depending on the HBV residual risk monitoring based on serologic testing and corresponding estimation methods. This paper reviews main HBV residual risk findings worldwide and the methods based on serology used for their calculation with repeat donors, as well as their extension to the first-time donors. Two artificial datasets with high (4.36%) and low (0.48%) HBV prevalence were generated to test the performance of five methods: the original incidence/window-period model based solely on HBsAg, its modification by Soldan in 2003, the Müller-Breitkreutz model, the HBsAg yield model, and its extension to include anti-HBc seroconversions within a year. The last model was closest to the true values of residual risk and had smallest variation of the estimates in both high and low prevalence data. It may be used for residual risk evaluation in relatively small samples, such as regional blood banks data.

show abstract

Current incidence and residual risk of hepatitis B infection among blood donors in the United States

Cited by 107 publications

References 21 publications

Recent advances toward defining the benefits and risks of erythrocyte transfusions in neonates

Recent advances toward defining the benefits and risks of erythrocyte transfusions in neonates

The underlying mechanisms for the “isolated positivity for the hepatitis B surface antigen (HBsAg)” serological profile

Residual Risk of Hepatitis-B-Infected Blood Donations: Estimation Methods and Perspectives

Contact Info

Product

Resources

About